AntiCTLA-4 antibody adjuvant therapy in melanoma

Seminars in Oncology

Volumn 37, Issue 5, 2010, Pages 455-459

  Eggermont, Alexander M M ^a   Testori, Alessandro ^b   Maio, Michele ^c   Robert, Caroline ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBINTERFERON ALPHA2B; ALPHA2A INTERFERON; C REACTIVE PROTEIN; CANVAXIN; GANGLIOSIDE GM2; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IPILIMUMAB; PEPTIDE VACCINE; PLACEBO; TEMOZOLOMIDE; TICILIMUMAB; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CP-675,206; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY;

CANCER ADJUVANT THERAPY; CANCER SURVIVAL; COLITIS; DERMATITIS; DIARRHEA; DRUG EFFICACY; HUMAN; IMMUNOMODULATION; LYMPH NODE METASTASIS; MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; DOSE RESPONSE; IMMUNOLOGY; PATHOLOGY; SKIN TUMOR; SURVIVAL;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERFERON-ALPHA; MELANOMA; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 78449233837     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2010.09.009     Document Type: Article

References (42)

1. A.M. Eggermont, and M. Gore Randomized adjuvant therapy trials in melanoma: surgical and systemic Semin Oncol 34 2007 509 515
2. A.M. Eggermont, and J.M. Kirkwood Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 40 2004 1825 1836
3. P. Hersey, A.S. Coates, and W.H. McCarthy Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial J Clin Oncol 20 2002 4181 4190
4. V.K. Sondak, P.Y. Liu, and R.J. Tuthill Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group J Clin Oncol 20 2002 2058 2066
5. M.K. Wallack, M. Berenji, K. Alam, and A.A. Bartolucci Ten-year analysis of vaccinia melanoma oncolysate (VMO) phase III trial [abstract 19031] J Clin Oncol 28 Suppl 2010
6. D. Morton, N. Mozzillo, and J. Thompson An international, randomised, phase III trial of BCG plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional nodes or distant sites [abstract] J Clin Oncol 25 Suppl 2007 8508
7. J.M. Kirkwood, J.G. Ibrahim, and J.A. Sosman High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801 J Clin Oncol 19 2001 2370 2380
8. A.M. Eggermont, S. Suciu, and W. Ruka EORTC 18961: post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results [abstract] J Clin Oncol 26 Suppl 2008 9004
9. A.M.M. Eggermont Therapeutic vaccines in solid tumours: can they be harmful? Eur J Cancer 45 2009 2087 2090
10. A.M.M. Eggermont, S. Suciu, and P. Rutkowski Randomized phase III trial comparing postoperative adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation in stage II (T3-T4N0M0) melanoma: final results of study EORTC 18961 [abstract 8505] J Clin Oncol 28 Suppl 2010
11. D.H. Lawson, S.J. Lee, A.A. Tarhini, K.A. Margolin, M.S. Ernstoff, and J.M. Kirkwood E4697: phase III cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III-IV melanoma [abstract 8504] J Clin Oncol 28 Suppl 2010
12. M.B. Faries, E.C. Hsueh, X. Ye, M. Hoban, and D.L. Morton Impact of GM-CSF on vaccination with an allogeneic whole-cell melanoma vaccine Clin Cancer Res 15 2009 7029 7035
13. C.L. Slingluff, G.R. Pettron, and W. Cison Effect of GM-CSF on circulating CD8+ and CD4+ T cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial Clin Cancer Res 15 2009 7036 7044
14. A.M.M. Eggermont Immunostimulation versus immunosuppression after multiple vaccinations: the woes of therapeutic vaccine development Clin Cancer Res 15 2009 6745 6747
15. A.M.M. Eggermont The role interferon-alpha in malignant melanoma remains to be defined Eur J Cancer 37 2001 2147 2153
16. E.T. Creagan, R.J. Dalton, and D.L. Ahmann Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma J Clin Oncol 13 1995 2776 2783
17. J.M. Kirkwood, M.H. Strawderman, M.S. Ernstoff, T.J. Smith, E.C. Borden, and R.H. Blum Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684 J Clin Oncol 14 1996 7 17
18. J.M. Kirkwood, J.G. Ibrahim, and V.K. Sondak High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190 J Clin Oncol 18 2000 2444 2459
19. K.M. McMasters, M.I. Ross, and D.S. Reintgen Final results of the Sunbelt trial [abstract 9003] J Clin Oncol 26 Suppl 2008 May 20
20. A.M. Eggermont, S. Suciu, and R. MacKie Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial Lancet 366 2005 1189 1196
21. J. Hansson, S. Aamdal, L. Bastholt, M. Hernberg, B. Nilsson, U. Stierner, and H. von der Maase Results of the Nordic radomized adjuvant trial of intermediate-doe interferon alfa-2b in high-risk melanoma [abstract 4] Eur J Cancer 5 Suppl 2007
22. J.J. Grob, B. Dreno, and P. de la Salmonire Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases Lancet 351 1998 1905 1910
23. H. Pehamberger, H.P. Soyer, and A. Steiner Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma Austrian Malignant Melanoma Cooperative Group J Clin Oncol 16 1998 1425 1429
24. D.A. Cameron, M.C. Cornbleet, and R.M. Mackie Adjuvant interferon alpha 2b in high risk melanomathe Scottish study Br J Cancer 84 2001 1146 1149
25. B.W. Hancock, K. Wheatley, and S. Harris Adjuvant interferon in high-risk melanoma: the AIM HIGH StudyUnited Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma J Clin Oncol 22 2004 53 61
26. N. Cascinelli, F. Belli, and R.M. MacKie Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial Lancet 358 2001 866 869
27. C. Garbe, P. Radny, and R. Linse Adjuvant low-dose interferon α2a with or without dacarbazine compared with surgery alone: a prospective- randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis Ann Oncol 19 2008 1195 1201
28. U.R. Kleeberg, S. Suciu, and E.B. Brcker Final results of the EORTC 18871/DKG 80-1 randomised phase III trial rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis Eur J Cancer 40 2004 390 402
29. K. Wheatley, N. Ives, and B. Hancock Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials Cancer Treat Rev 29 2003 241 252
30. K. Wheatley, N. Ives, and A.M. Eggermont Interferon-α as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials [abstract 8526] J Clin Oncol 25 Suppl 2007
31. A.M. Eggermont, S. Suciu, and M. Santinami Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial Lancet 372 2008 117 126
32. A.M. Eggermont, S. Suciu, and A. Testori Ulceration of primary melanoma and responsiveness to adjuvant interferon therapy: analysis of the adjuvant trials EORTC18952 and EORTC18991 in 2644 patients [abstract 9007] J Clin Oncol 18 Suppl 2009
33. L.H. Camacho, S. Antonia, and J. Sosman Phase I/II trial of tremelimumab in patients with metastatic melanoma J Clin Oncol 27 2009 1075 1081
34. A. Ribas, A. Hauschild, and R. Kefford Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma [abstract 9011] J Clin Oncol 26 Suppl 2008
35. A.A. Tarhini, S.J. Moschos, and H. Tawbi Phase II evaluation of tremelimumab (Treme) combined with high-dose interferon alpha-2b (HDI) for metastatic melanoma [abstract 8524] J Clin Oncol 28 Suppl 2010
36. E.M. Hersh, J.S. Weber, and J.D. Powderly Disease control and long-term survival in chemotherapy-naive patients with advanced melanoma treated with ipilimumab (MDX- 010) with or without dacarbazine [abstract 9022] J Clin Oncol 26 Suppl 2008
37. P. Attia, G.Q. Phan, and A.V. Maker Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4 J Clin Oncol 23 2005 6043 6053
38. S.G. Downey, J.A. Klapper, and F.O. Smith Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade Clin Cancer Res 13 2007 6681 6688
39. K.E. Beck, J.A. Blansfield, and K.Q. Tran Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 J Clin Oncol 24 2006 2283 2289
40. J.D. Wolchok, B. Neyns, and G. Linette Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study Lancet Oncol 11 2010 155 164
41. D. Schadendorf, J. Wolchok, and B. Neyns Activity of ipilimumab at 10mg/kg in patients with advanced melanoma is independent of baseline prognostic factors Eur J Cancer Suppl 7 2009 579
42. F.S. Hodi, S.J. O'Day, and D.F. McDermott Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723